Clinical Research Directory
Browse clinical research sites, groups, and studies.
PROMET-BR - Molecular Profiling of Metastatic Prostate Cancer: a Brazilian Cohort
Sponsor: AstraZeneca
Summary
PROMET-BR is an observational, retrospective and prospective real-world study in Brazil designed to characterize clinically relevant molecular alterations in metastatic prostate cancer and explore their association with patient outcomes in routine practice. The study will be conducted within Oncoclínicas \& Co and will integrate centralized biomarker testing performed at OC Precision Medicine laboratories with retrospectively assembled clinical data from electronic health records (EHRs) from participating sites. Treatments are not assigned by the protocol; patients receive standard-of-care palliative systemic therapy at the discretion of their treating physicians.
Official title: A Retrospective and Prospective Study Aiming to Characterize Molecular Alterations and Clinical Outcomes of Metastatic Prostate Cancer in a Real-world Cohort of Patients Eligible to Palliative Systemic Therapy at Oncoclínicas & Co Group
Key Details
Gender
MALE
Age Range
18 Years - 99 Years
Study Type
OBSERVATIONAL
Enrollment
100
Start Date
2026-04-30
Completion Date
2027-03-31
Last Updated
2026-05-01
Healthy Volunteers
No
Conditions
Interventions
Archived FFPE tissue biopsy and/or newly acquired liquid biopsy for molecular profiling.
The exposure/intervention under investigation is the use of archived FFPE tissue biopsy and/or newly acquired liquid biopsy for molecular profiling.
Locations (1)
Research Site
São Paulo, Brazil